What is Emulate?
Headquartered in Boston, Massachusetts, and established in 2013, Emulate is at the forefront of the Organs-on-Chips industry. The company specializes in developing sophisticated micro-engineered environments that simulate the physiological responses of human organs. This technology serves as a vital bridge between traditional cell culture and animal testing, offering researchers a more accurate, human-centric approach to evaluating drug efficacy and toxicity. By providing a platform that models both healthy and diseased states, Emulate enables pharmaceutical and biotechnology firms to accelerate their research pipelines while reducing the reliance on conventional, often less predictive, testing methodologies.
How much funding has Emulate raised?
Emulate has raised a total of $169M across 7 funding rounds:
Series A
$12M
Series B
$17M
Grant
$2M
Private Equity
$745K
Series C
$36M
Other Financing Round
$19.3M
Series E
$82M
Series A (2014): $12M with participation from Cedars-Sinai and NanoDimension
Series B (2016): $17M led by ATEL Capital Group, Cedars-Sinai, Laboratory Corporation of Americau00ae Holdings, NanoDimension, OS Fund, and ALS Finding a Cure
Grant (2017): $2M supported by National Center for Advancing Translational Sciences
Private Equity (2017): $745K, investors not publicly disclosed
Series C (2018): $36M backed by Starlight Ventures, SciFi VC, ALS Investment Fund, and Founders Fund
Other Financing Round (2020): $19.3M with participation from Cedars-Sinai, Founders Fund LLC, NanoDimension, Blue Ivy Ventures, ALSInvestment Fund, and Northpond Ventures LLC
Series E (2021): $82M led by Perceptive Advisors and Northpond Ventures
Key Investors in Emulate
Perceptive Advisors
A New York-based investment firm managing approximately $7 billion in assets, specializing in funding innovative healthcare and life sciences technologies.
Northpond Ventures
A venture capital firm focused on building and empowering breakthrough businesses in science and technology, with a strong emphasis on the life sciences sector.
Founders Fund
A prominent venture capital firm that invests in transformative companies across various stages, known for backing industry-defining organizations like SpaceX and Stripe.
What's next for Emulate?
With the infusion of capital from its latest strategic investment, Emulate is well-positioned to scale its commercial operations and expand the utility of its Organs-on-Chips platform across global research markets. The company is expected to focus on deepening its partnerships with major pharmaceutical entities and academic institutions to standardize its technology in clinical workflows. As the industry shifts toward more precise, personalized medicine, Emulate's ability to provide high-fidelity human biological data will likely remain a key driver of its long-term growth and competitive advantage in the life sciences ecosystem.
See full Emulate company page
